Claim No. 2015 HCV 03627 ...

The project is expected to generate direct employment for around 1,000 people and indirect employment for nearly 2,000 more, ...

Atea Pharmaceuticals (AVIR) will present the Company’s strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco. Atea ended 2025 ...

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...

In the past one month, Ashok Leyland has outperformed the market by surging 18 per cent, as compared to 1.3 per cent decline ...

Atea Pharmaceuticals, Inc. Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

Housing Works, a housing organization dedicated to fostering stability and affordability in Central Oregon, has announced ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...

Honoring Five Decades of Progress, Commitment, and Support for Liver Patients FAIRFIELD, N.J., Jan. 5, 2026 /PRNewswire/ -- American Liver Foundation (ALF) proudly announces its 50th anniversary, ...

Researchers at the University of Washington have developed a rapid test that quickly detects hepatitis C, but insurance ...

A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...